Turning in locomotion might appear simple at a glance, but it encompasses an intricate orchestration of neural circuits involving multiple brain regions, most notably the basal ganglia and motor cortex. The basal ganglia, with the globus pallidus as a central nucleus, serves as a hub for integrating cortical motor commands and facilitating smooth movement transitions. In Parkinson’s disease, characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta, this delicate balance is severely disrupted. Previous research has highlighted beta frequency (13–30 Hz) oscillatory activity as a pathological hallmark in the basal ganglia-cortical network that correlates with bradykinesia and rigidity, yet the specific dynamics mediating complex actions such as turning remained elusive until now.

The research team employed advanced electrophysiological techniques involving simultaneous recordings from the motor cortex and globus pallidus in Parkinsonian animal models, complemented by sophisticated computational analyses of beta frequency coherence and phase relationships. They meticulously quantified the patterns of beta synchronization during naturalistic turning behaviors and compared these with normal locomotion. Their data revealed a striking phenomenon: excessive and persistent beta synchrony between the cortex and pallidum, which was markedly heightened during impaired turning episodes. This hyper-synchronization appeared to “lock” motor circuits in a rigid state, preventing the flexible updating of motor commands essential for directional shifts.

Interestingly, the study delineates the temporal specificity of cortico-pallidal beta dynamics, highlighting that aberrant beta bursts were not uniform but occurred in distinct phases relative to the initiation and execution of turning. Early beta overactivity hindered preparatory motor planning processes, whereas sustained beta coherence during the turning itself interfered with motor execution and feedback integration. This dual-phase disruption underscores the multifaceted role of beta oscillations in motor control and reveals why turning—a movement demanding rapid, coordinated changes in direction— is disproportionately affected in Parkinson’s disease compared to simpler linear locomotion.

Beyond the basal ganglia, the researchers also discuss how abnormal beta activity propagates through the broader motor network, including the supplementary motor area and premotor cortex, effectively “entraining” widespread motor regions into dysfunctional synchrony. This pathological network state parallels clinical observations of freezing of gait and festination—phenomena where patients experience sudden motor blocks or involuntary hastening—often triggered during turning or negotiating obstacles. These insights bridge neurophysiological data with behavioral manifestations, providing a holistic framework for understanding motor impairments in Parkinson’s disease.

Therapeutically, the findings have profound implications. Current treatments such as deep brain stimulation (DBS) targeting the subthalamic nucleus or globus pallidus interna exert their beneficial effects partly by disrupting beta oscillations. However, this study suggests that precisely modulating the cortico-pallidal beta interaction, perhaps through closed-loop DBS systems or novel neuromodulatory devices, could optimize symptom relief specifically for turning and complex movement deficits that remain challenging to address. Advances in non-invasive methods such as transcranial alternating current stimulation (tACS) might also leverage these insights to tailor beta rhythm disruption without surgical intervention.

Crucially, the authors emphasize that beta oscillations, while pathological when exaggerated, are also integral to normal motor function, reflecting a need for nuanced interventions that restore physiological beta dynamics rather than bluntly suppressing all beta activity. This perspective aligns with emerging paradigms viewing Parkinson’s disease as a circuit disorder characterized by abnormal neural dynamics rather than purely neurodegeneration, advocating for precision neuromodulation grounded in a deep understanding of network oscillations.

The study’s methodology incorporated a multidisciplinary approach, combining in vivo electrophysiology, behavioral assays of turning, computational modeling, and pharmacological manipulations to systematically dissect the contribution of dopamine depletion to cortico-pallidal beta abnormalities. The researchers demonstrated that restoring dopaminergic tone via pharmacotherapy partially normalized beta bursts and improved turning performance, reinforcing the dopamine-beta link as a pathogenetic axis in Parkinson’s disease.

Moreover, the research highlights the heterogeneity within Parkinson’s disease, noting variability in beta dynamics across subjects and disease stages. This variability suggests potential biomarkers that could stratify patients and personalize neuromodulatory interventions. By mapping beta synchrony signatures to clinical metrics of turning impairment, future clinical applications could non-invasively monitor disease progression and therapeutic efficacy.

From a mechanistic standpoint, the study contributes to the understanding of how beta oscillations arise within the basal ganglia-thalamo-cortical loop. The globus pallidus, with its distinct external (GPe) and internal (GPi) segments, participates differentially in generating and propagating pathological beta rhythms. The authors propose refined models in which cortico-pallidal beta synchronization involves reciprocal excitatory-inhibitory feedback loops, modulated by dopamine-dependent changes in synaptic plasticity and intrinsic neuronal properties. This intricate interplay provides fertile ground for further experimental and theoretical investigation into basal ganglia oscillopathies.

The research also touches on potential links between cortico-pallidal beta dynamics and non-motor symptoms in Parkinson’s disease, such as cognitive inflexibility and impaired motor learning. Given that beta oscillations are implicated broadly in maintaining the current motor or cognitive state, their pathological perpetuation might underlie the difficulty patients experience in switching tasks or adapting to new motor demands, phenomena particularly evident during complex behaviors like turning.

Importantly, this study represents a foundational advance in Parkinson’s disease research, charting a novel conceptual territory by focusing on turning-specific motor dysfunctions rather than generic bradykinesia or tremor. By dissecting the oscillatory mechanisms that uniquely impair turning, the authors have identified a critical target for therapeutic innovation with potentially outsized impact on patient mobility and quality of life.

The translational potential of these findings is vast. Neurologists and clinicians can harness this mechanistic insight to refine symptom assessment scales, incorporating turning-specific biomarkers for early diagnosis and progression monitoring. Furthermore, engineers designing next-generation neuromodulation devices may utilize real-time beta oscillation detection to implement adaptive stimulation protocols, precisely timed to disrupt pathological synchronization and restore normal motor flow during turning.

Future directions highlighted by the authors include extending these investigations to human patients using non-invasive electrophysiology and leveraging machine learning algorithms to decode individual beta patterns predictive of turning difficulty. Additionally, exploration into molecular modulators of beta oscillations could complement electrical neuromodulation approaches, offering combinatory strategies to normalize network dynamics.

Ultimately, this landmark study elegantly demonstrates how cutting-edge neuroscience can unravel the complex circuitry underlying a single, yet highly debilitating motor behavior in Parkinson’s disease. By illuminating the cortico-pallidal beta dynamics as a core element in turning impairment, it lays the groundwork for transformative advances in both fundamental understanding and clinical management of Parkinson’s motor deficits.

Subject of Research: Understanding the neural oscillatory mechanisms, specifically cortico-pallidal beta dynamics, underlying impaired turning movements in Parkinson’s disease.

Article Title: Cortico-pallidal beta dynamics underlie impaired turning in Parkinson’s disease.

Article References:
Shukla, P.D., Bath, J.E., Louie, K.H. et al. Cortico-pallidal beta dynamics underlie impaired turning in Parkinson’s disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01421-9

Image Credits: AI Generated

The subthalamic nucleus forms part of the basal ganglia circuitry, playing a critical role in movement regulation. Parkinson’s disease, characterized by dopaminergic neuron degeneration, disrupts these basal ganglia pathways, leading to the hallmark motor impairments such as bradykinesia, rigidity, and tremor. Deep brain stimulation (DBS) targeting the STN has become a cornerstone in managing advanced PD, primarily operated via implanted electrodes that deliver electrical impulses to modulate dysfunctional neural activity. However, fine-tuning DBS parameters and maximizing treatment efficacy over years remain challenging due to variable biomarker reliability and underlying neural plasticity.

The study uniquely addresses this clinical gap by examining the stability of two distinct physiomarkers derived from LFP recordings: periodic oscillatory activities, such as beta-band rhythms, and aperiodic components, which reflect broadband spectral features potentially linked to neural excitation-inhibition balance. Traditionally, periodic beta oscillations (~13-30 Hz) have been extensively studied, with elevated beta power correlating negatively with motor performance and responsiveness to dopaminergic therapies. Yet, aperiodic neural dynamics, representing scale-free fluctuations in the frequency domain, have emerged as complementary indicators of underlying neural state and are gaining traction in neurophysiological research.

Employing an advanced longitudinal design, Stam et al. implanted directional DBS leads capable of chronic LFP monitoring in a cohort of PD patients. This approach permitted recording subthalamic signals over an extended timeframe of months to years, circumventing the limitations inherent in short-term laboratory assessments. By systematically analyzing the spectral features from these datasets, the researchers quantified the intra-individual variability of periodic beta oscillations and aperiodic broadband components, thereby assessing their temporal robustness.

A critical revelation from the analysis was the remarkable long-term consistency of both physiomarkers. Beta-band oscillations demonstrated stable oscillatory peaks in frequency and power, maintaining their spatial focality within the STN despite ongoing disease progression and therapeutic adjustments. Concurrently, the aperiodic exponent, which characterizes the slope of the power spectral density, showed minimal drift over time, suggesting that the neural excitation-inhibition balance indexed by this feature is a steadfast characteristic of subthalamic physiology in PD patients.

This constancy has profound implications for the design of adaptive DBS systems, also known as closed-loop neuromodulation. These systems rely on feedback from reliable biomarkers to dynamically adjust stimulation parameters in response to the patient’s neural state, aiming to enhance clinical outcomes and reduce side effects. The demonstration that both periodic and aperiodic features endure longitudinally argues strongly for their incorporation into real-time DBS control algorithms. Unlike biomarkers susceptible to transient fluctuations, these physiomarkers could serve as stable anchors facilitating personalized neuromodulation that adapts intelligently over the course of treatment.

Moreover, the distinction between periodic and aperiodic components opens novel vistas in understanding PD pathophysiology. While pathological beta synchrony has long been associated with motor impairment, the aperiodic spectral features may relate more fundamentally to network excitation levels and synaptic homeostasis within the STN and its broader basal ganglia context. The preserved aperiodic exponent suggests a maintained cortical-subcortical balance or a stable underlying neural noise floor, both of which could influence how the basal ganglia circuits process motor commands and respond to dopaminergic modulation.

This study also highlights the technical advancements enabling such comprehensive long-term monitoring. The use of directional DBS electrodes enhances spatial resolution, allowing precise localization of physiomarker sources and minimizing contamination from adjacent neural structures. Coupled with sophisticated signal processing pipelines capable of disentangling oscillatory and non-oscillatory signal components, these innovations are ushering in an era where nuanced understanding of brain oscillations can be integrated into everyday clinical practice.

Despite these advances, the authors also caution about inherent complexities in interpreting LFP data. Factors such as individual anatomical variability, electrode positioning, medication status, and disease heterogeneity contribute to subtle variations in the recorded signals. Therefore, while physiomarkers show resilience, developing robust algorithms capable of accommodating these inter- and intra-individual differences remains an ongoing challenge. Nonetheless, this comprehensive dataset provides an invaluable foundation for translational research aimed at refining biomarker-guided DBS paradigms.

Importantly, the findings underscore the necessity of incorporating both periodic and aperiodic signal characteristics when defining physiomarkers in PD. Prior DBS optimization strategies have predominantly fixated on beta oscillations as the primary feedback signal, which may only tell part of the story. By integrating aperiodic signal metrics, future approaches could harness complementary neurophysiological information reflective of broader circuit dynamics, potentially enhancing therapeutic precision and patient-specific customization.

Furthermore, these insights carry broader implications beyond Parkinson’s disease. The methodology and analytical framework developed in this research can be adapted to other neurological disorders where abnormal neural oscillations and altered excitation-inhibition balances play crucial roles, such as dystonia, essential tremor, and epilepsy. The notion of dissecting and tracking discrete spectral components over long periods sets a new standard for personalized neuromodulation therapies across diverse clinical contexts.

This study also invigorates discussions on the biological basis of aperiodic neural activity, a topic garnering increasing attention in systems neuroscience. Aperiodic activity has been posited to reflect fundamental aspects of cortical microcircuit function, including synaptic input distributions and membrane potential fluctuations. The stability of the aperiodic exponent in PD patients’ STN offers empirical support for its role as a trait-like neural signature, opening avenues for further investigation into how disease processes perturb these fundamental electrical properties.

From a clinical viewpoint, the ability to track physiomarker stability longitudinally enhances patient monitoring and prognosis. Stable neural markers provide clinicians with reliable indicators to evaluate disease progression, therapeutic response, and potential adjustments in DBS programming. Moreover, continuous LFP monitoring embedded within implanted devices could facilitate remote, real-time assessment of PD motor states, reducing the need for frequent clinical visits and fostering proactive disease management.

As the field moves towards precision neuromodulation, the contribution of Stam and colleagues represents a significant paradigm shift. By meticulously validating the long-term consistency of physiomarkers in the subthalamic nucleus, this work lays the groundwork for next-generation closed-loop DBS systems that are both adaptive and durable. Future studies expanding these findings to larger, more diverse patient populations will be critical in generalizing these principles and integrating them into routine clinical workflows.

In sum, this landmark investigation redefines our understanding of Parkinsonian neurophysiology, highlighting that both oscillatory beta rhythms and aperiodic spectral features are not transient artifacts but rather stable signatures embedded within the subthalamic circuitry. These findings empower researchers and clinicians alike to envision a future where tailored neuromodulation strategies leverage reliable electrophysiological physiomarkers, ultimately improving quality of life for millions affected by Parkinson’s disease worldwide.

Subject of Research:
Long-term stability of periodic and aperiodic physiomarkers in subthalamic local field potentials in Parkinson’s disease

Article Title:
Long-term consistency of aperiodic and periodic physiomarkers in subthalamic local field potentials in Parkinson’s disease

Article References:

Stam, M.J., van Wijk, B.C.M., Buijink, A.W.G. et al. Long-term consistency of aperiodic and periodic physiomarkers in subthalamic local field potentials in Parkinson’s disease. npj Parkinsons Dis. 11, 204 (2025). https://doi.org/10.1038/s41531-025-01053-5

Image Credits: AI Generated